Ownership and insider activity for Pluri Inc. (PLUR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology.
Price
| Price | $1.14 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | IL |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.7M | $8.8M | $4.1M | $8.8M | $31.2M | $9.8M | $5.4M | $6.8M | $5.9M | $3.5M |
| Short-term Investments | $21.4M | $21.1M | $19.6M | $37.5M | $33.7M | $45.2M | $34.8M | $23.2M | $14.7M | $4.3M |
| Receivables | $1.2M | $847000 | $1.4M | $1.6M | $1.5M | $1.3M | $527000 | $638000 | $722000 | $219000 |
| Inventory | 0 | 0 | $692000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $29.0M | $32.0M | $26.4M | $48.5M | $67.4M | $57.7M | $41.4M | $31.1M | $22.1M | $8.7M |
| Property, Plant & Equipment | $7.3M | $5.7M | $3.8M | $3.8M | $2.2M | $9.0M | $8.3M | $7.2M | $8.7M | $7.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $3.1M | $3.1M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.8M | $2.6M |
| Total Assets | $37.5M | $39.0M | $31.3M | $65.5M | $93.5M | $68.1M | $50.8M | $39.5M | $38.7M | $24.9M |
| Accounts Payable | $2.0M | $3.3M | $2.3M | $2.0M | $2.5M | $1.8M | $1.8M | $964000 | $866000 | $702000 |
| Short-term Debt | 0 | 0 | 0 | $1.0M | 0 | 0 | 0 | 0 | $27.3M | $27.4M |
| Total Current Liabilities | $5.4M | $8.5M | $8.2M | $8.0M | $11.5M | $6.8M | $5.6M | $4.5M | $32.3M | $32.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | $23.9M | $21.7M | $23.5M | $24.0M | 0 | 0 |
| Total Liabilities | $7.3M | $10.5M | $9.5M | $9.4M | $36.4M | $35.9M | $35.5M | $34.1M | $39.5M | $42.3M |
| Retained Earnings | -$189.6M | -$215.7M | -$251.0M | -$280.2M | -$330.0M | -$371.3M | -$399.6M | -$420.5M | -$443.1M | -$466.9M |
| Total Equity | $30.3M | $28.5M | $21.8M | $56.1M | $57.2M | $30.0M | $13.4M | $96000 | -$6.8M | -$23.0M |
| Total Debt | 0 | 0 | 0 | $1.6M | $24.6M | $28.8M | $29.9M | $29.6M | $34.0M | $34.9M |
| Net Debt | -$26.1M | -$29.9M | -$23.7M | -$44.8M | -$40.4M | -$26.2M | -$10.3M | -$373000 | $13.4M | $27.1M |
| Working Capital | $23.6M | $23.5M | $18.2M | $40.5M | $55.9M | $50.9M | $35.8M | $26.7M | -$10.2M | -$24.0M |
Financial Health
| Debt / Equity | -1.81 |
| Current Ratio | 0.33 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -17.73 |
Profitability
| Return on Equity | 203.55% |
| Return on Invested Capital | -117.79% |
| Return on Assets | -100.41% |
| Gross Margin | 19.00% |
| Operating Margin | -2412.14% |
| Net Margin | -2424.75% |
Related companies: ANTX · BOLD · IBIO · INTS · ITRM · JSPR · NXTC
Explore sector: Healthcare · Biotechnology
More sections of PLUR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks